HAINAN HULUWA PHARMACEUTICAL GROUP CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.06 CNY | +1.21% |
|
-2.42% | -33.64% |
| 06-19 | Huluwa Pharmaceutical Gets Nod to Market Asthma Drug for Kids | MT |
| 05-01 | Huluwa Pharmaceutical Gets Nod to Register Two Drugs | MT |
| Sales 2022 | 1.52B 209M 286M | Sales 2023 | 1.91B 262M 359M | Capitalization | 6.07B 835M 1.14B |
|---|---|---|---|---|---|
| Net income 2022 | 85M 11.71M 16.03M | Net income 2023 | 106M 14.6M 19.99M | EV / Sales 2022 | 4.37 x |
| Net Debt 2022 | 204M 28.04M 38.41M | Net Debt 2023 | 759M 105M 143M | EV / Sales 2023 | 3.58 x |
| P/E ratio 2022 |
76.3
x | P/E ratio 2023 |
56.1
x | Employees | 2,468 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 20.88% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.21% | ||
| 1 week | -2.42% | ||
| Current month | -9.69% | ||
| 1 month | -13.28% | ||
| 3 months | -23.32% | ||
| 6 months | -34.51% | ||
| Current year | -33.64% |
1 week
9.82
10.38
1 month
9.8211.59
Current year
9.5115.58
1 year
9.5120.09
3 years
9.5131.16
5 years
6.2349.88
10 years
6.2349.88
| Managers | Title | Age | Since |
|---|---|---|---|
Jing Ping Liu
CEO | Chief Executive Officer | 54 | 07-11-30 |
Peng Xu
CHM | Chairman | 61 | 10-02-28 |
Hui Yu
DFI | Director of Finance/CFO | 40 | 22-07-07 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Gui Hua Wang
BRD | Director/Board Member | 63 | 18-11-15 |
Jing Ping Liu
CEO | Chief Executive Officer | 54 | 07-11-30 |
Ping Liu
BRD | Director/Board Member | 51 | 12-02-29 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-21 | 10.06 | +1.21% | 1,116,300 |
| 24-06-20 | 9.94 | -2.07% | 1,573,700 |
| 24-06-19 | 10.15 | -1.36% | 1,140,000 |
| 24-06-18 | 10.29 | +0.29% | 1,091,400 |
| 24-06-17 | 10.26 | -0.48% | 964,800 |
End-of-day quote Shanghai S.E., June 20, 2024
More quotes
Hainan Huluwa Pharmaceutical Group Co Ltd is a China-based company principally involved in the research and development, manufacturing and sales of Chinese patent medicines and chemical drugs. Its products are used in the pharmaceutical fields of respiratory system, digestive system, systemic anti-infection, including pediatric lung heat cough asthma granules, bromhexine hydrochloride for injection, compound Banlangen granules, Keke tablets, omeprazole enteric-coated capsules , Changyanning (capsules and granules), omeprazole sodium for injection, sodium diisopropylamine dichloroacetate for injection and cefixime dispersible tablets, among others. The Company also provides gynecological medicine, cardiovascular system medicine and neurological system medicine preparation products. The Company operates its businesses in the domestic market.
Sector
Pharmaceuticals
Calendar
2024-08-25
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -33.64% | 554M | |
| +51.63% | 796B | |
| +41.51% | 628B | |
| -5.10% | 358B | |
| +19.90% | 331B | |
| +9.95% | 301B | |
| +17.66% | 244B | |
| +3.39% | 228B | |
| +10.75% | 214B | |
| +6.99% | 165B |
- Stock Market
- Equities
- 605199 Stock
